La chaîne d'options affiche les données clés des options sur actions de Hill & Smith à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Hill & Smith..

Hill & Smith (OTC:HSHPF) Stock, Chaîne d'Options

Hill & Smith PLC creates sustainable infrastructure and safe transport through innovation. It is organized into three main business divisions. Galvanizing Services increase the sustainability and maintenance-free life of steel products including structural steelwork, lighting, bridges, agricultural and other products for the industrial and infrastructure markets. Engineered Solutions supplies engineered steel and composite solutions for a wide range of infrastructure markets including energy generation and distribution, marine, rail, and housing. Roads & Security division supplies products and services to support road and highway infrastructure including temporary and permanent road safety barriers, renewable energy lighting and power solutions, and Intelligent Traffic Solutions.

HILL & SMITH HOLDINGS by Hill & Smith Holdings Plc.

Hill & Smith PLC

Analysts' ratings for Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ross Stores and provided 12-month price targets. The average target is $154.4, accompanied by a high estimate of $175.00 and a low estimate of $128.00. This current average represents a 4.65% decrease from the previous average price target of $161.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1747252884_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Ross Stores's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$128.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$146.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$163.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$156.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ross Stores. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ross Stores compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Ross Stores's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ross Stores's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ROST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ross Stores analyst ratings.</a>
<h2>Discovering Ross Stores: A Closer Look</h2>
Ross Stores operates as an off-price apparel and accessories retailer with the majority of its sales derived from its Ross Dress for Less banner. The company opportunistically procures excess brand-name merchandise made available via manufacturing overruns and retail liquidation sales at a 20%-60% discount to full prices. As such, its stores are often filled with a vast array of stock-keeping units, each with minimal product depth that creates a treasure hunt shopping experience. The firm's more than 1,800 Ross Dress for Less stores are primarily located in densely populated suburban communities and typically serve middle-income consumers. Ross also operates about 350 DD's Discounts chains targeting lower-income shoppers.
<h3>Financial Insights: Ross Stores</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Ross Stores's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -1.83% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Ross Stores's net margin excels beyond industry benchmarks, reaching 9.92%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ross Stores's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.89% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Ross Stores's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ross Stores's debt-to-equity ratio is below the industry average at 1.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ROST

A Glimpse Into The Expert Outlook On Ross Stores Through 15 Analysts

MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 38.71 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $24.30 million which beat the analyst consensus estimate of $24.11 million by 0.79 percent. This is a 22.52 percent increase over sales of $19.83 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

MDXH

MDxHealth Q1 EPS $(0.19) Misses $(0.13) Estimate, Sales $24.30M Beat $24.11M Estimate

Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) affirms FY2025 sales outlook from $50.20 million-$65.80 million to $50.20 million-$65.80 million vs $79.47 million estimate.

Guidance

Xos Affirms FY2025 Sales Guidance of $50.20M-$65.80M vs $79.47M Est

In the last three months, 11 analysts have published ratings on Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $88.18, along with a high estimate of $108.00 and a low estimate of $69.00. Observing a downward trend, the current average is 4.72% lower than the prior average price target of $92.55. 
<img src="https://www.benzinga.com/files/images/story/2025/1747252871_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Kontoor Brands among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kontoor Brands. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Kontoor Brands compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Kontoor Brands's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Kontoor Brands's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KTB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kontoor Brands analyst ratings.</a>
<h2>Get to Know Kontoor Brands Better</h2>
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
<h3>Kontoor Brands: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Kontoor Brands's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.32%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Kontoor Brands's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kontoor Brands's ROE stands out, surpassing industry averages. With an impressive ROE of 10.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Kontoor Brands's ROA stands out, surpassing industry averages. With an impressive ROA of 2.58%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Kontoor Brands's debt-to-equity ratio is below the industry average. With a ratio of 1.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Kontoor Brands's Future

6 analysts have expressed a variety of opinions on Fox Factory Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Fox Factory Holding, revealing an average target of $31.17, a high estimate of $38.00, and a low estimate of $24.00. A decline of 16.14% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747252853_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Fox Factory Holding among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Bret Jordan</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fox Factory Holding. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fox Factory Holding compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Fox Factory Holding's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Fox Factory Holding's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FOXF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fox Factory Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Fox Factory Holding</h2>
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
<h3>Understanding the Numbers: Fox Factory Holding's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Fox Factory Holding's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 6.46%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Fox Factory Holding's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -73.15%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Fox Factory Holding's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -24.26%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Fox Factory Holding's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.45%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Fox Factory Holding's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FOXF

A Glimpse Into The Expert Outlook On Fox Factory Holding Through 6 Analysts

In the current market session, Lennox Intl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) stock price is at $588.83, after a 2.24% drop. However, over the past month, the company's stock increased by 7.48%, and in the past year, by 19.89%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747252842_0.png" alt="Past Year Chart" />

<h3>Comparing Lennox Intl P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lennox Intl has a lower P/E than the aggregate P/E of 30.16 of the Building Products industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747252842_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Lennox Intl Inc's Price Over Earnings

Across the recent three months, 8 analysts have shared their insights on Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $131.12, a high estimate of $158.00, and a low estimate of $100.00. Highlighting a 32.15% decrease, the current average has fallen from the previous average price target of $193.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1747252841_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Deckers Outdoor by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$127.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Deckers Outdoor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Deckers Outdoor compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Deckers Outdoor's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Deckers Outdoor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DECK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Deckers Outdoor analyst ratings.</a>
<h2>Discovering Deckers Outdoor: A Closer Look</h2>
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2024, Ugg and Hoka accounted for 52% and 42% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships, but also operates e-commerce in more than 50 countries and about 178 company-operated stores. It generated 67% of its fiscal 2024 sales in the United States.
<h3>Deckers Outdoor's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Deckers Outdoor showcased positive performance, achieving a revenue growth rate of 17.1% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Deckers Outdoor's net margin is impressive, surpassing industry averages. With a net margin of 25.0%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Deckers Outdoor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 18.82%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Deckers Outdoor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 12.41%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Deckers Outdoor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DECK

Analyst Expectations For Deckers Outdoor's Future

MidCap Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFIC#NYSE">MFIC</a>) short percent of float has fallen 4.71% since its last report. The company recently reported that it has 752 thousand shares sold short, which is 0.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>MidCap Financial Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747252840_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MidCap Financial has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MidCap Financial's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MidCap Financial's peer group average for short interest as a percentage of float is 3.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MFIC

Peering Into MidCap Financial's Recent Short Interest

Freeport-McMoRan's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) short percent of float has fallen 14.59% since its last report. The company recently reported that it has 22.54 million shares sold short, which is 1.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Freeport-McMoRan Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747252834_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Freeport-McMoRan has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Freeport-McMoRan's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Freeport-McMoRan's peer group average for short interest as a percentage of float is 4.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Freeport-McMoRan?

Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.11) by 13.51 percent. This is a 30 percent increase over losses of $(1.80) per share from the same period last year. The company reported quarterly sales of $5.88 million which missed the analyst consensus estimate of $10.17 million by 42.17 percent. This is a 55.33 percent decrease over sales of $13.16 million the same period last year.

Xos Q1 EPS $(1.26) Misses $(1.11) Estimate, Sales $5.88M Miss $10.17M Estimate

Selective Insurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NYSE">SIGI</a>) short percent of float has risen 3.96% since its last report. The company recently reported that it has 1.46 million shares sold short, which is 3.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.78 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Selective Insurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747252829_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Selective Insurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Selective Insurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Selective Insurance Gr's peer group average for short interest as a percentage of float is 2.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SIGI

Is the Market Bullish or Bearish on Selective Insurance Gr?

In the last three months, 4 analysts have published ratings on PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $11.0, a high estimate of $11.50, and a low estimate of $10.50. This current average represents a 7.41% decrease from the previous average price target of $11.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1747252829_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of PennantPark Floating Rate by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Diana</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.50</td>
<td>$12.50</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Vilas Abraham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$11.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PennantPark Floating Rate. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PennantPark Floating Rate compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PennantPark Floating Rate's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PennantPark Floating Rate's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PFLT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PennantPark Floating Rate analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind PennantPark Floating Rate</h2>
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
<h3>Financial Insights: PennantPark Floating Rate</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: PennantPark Floating Rate displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 22.52%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: PennantPark Floating Rate's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 95.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): PennantPark Floating Rate's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.08%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.27%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.39.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PFLT

4 Analysts Have This To Say About PennantPark Floating Rate

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced on Wednesday that it will invest at least $20 billion in the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">U.S. through 2030</a>.
Research and development, plus U.S. manufacturing, will receive the bulk of the spending.
The company also expects higher job creation within the communities where Sanofi and its partners are located, which will help <a href="https://www.benzinga.com/pressreleases/25/05/n45414947/sanofi-to-invest-at-least-20-billion-in-the-us-through-2030-growing-investments-in-science-and-exp" target="_blank" rel="noreferrer noopener">enhance the U.S. supply chain</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a>
Sanofi has 13,000 US-based employees, according to CEO Paul Hudson.
&#8220;Our expected investments in the US will be substantial and will help ensure the production of key medicines in the U.S.,&#8221; he added.
Sanofi also expects to partner with other domestic manufacturers to help ensure the production of medicines in the U.S.  
Earlier in May, U.S. President&nbsp;Donald Trump's&nbsp;signed an executive order to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The White House wants facilities to come on board at a faster rate. It <a href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">estimates</a> that it can currently take five to 10 years to build new pharmaceutical manufacturing capacity, which it calls "unacceptable from a national-security standpoint.&#8221;
It&#8217;s not just Sanofi. <a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S.:
<ul class="wp-block-list">
<li>Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm&nbsp;Becton, Dickinson, and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)  seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;announced that it will invest $50 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Bristol-Myers Squibb &amp; Co.'s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Christopher Boerner, chair and chief executive officer,&nbsp;<a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">shared</a>&nbsp;plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Statnews.</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is one pharma company that did not highlight investments in new manufacturing plants. The company noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">products in the U.S</a>.
Price Action: Sanofi stock is down 1.53% at $49.20 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45407486/novo-nordisk-inks-22-billion-deal-with-septerna-to-develop-oral-weight-loss-and-diabetes-drugs" target="_blank" rel="noreferrer noopener">Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

Movers

General

REGN

RHHBY

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

JP Morgan analyst Matthew R. Boss reiterated the Neutral rating on American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>), <a target="_blank" href="https://www.benzinga.com/quote/AEO/analyst-ratings" rel="noreferrer noopener">lowering the price forecast from $10 to $9.</a>
American Eagle shares fell <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45414387/american-eagle-stock-is-sliding-today-heres-why" rel="noreferrer noopener">nearly 15% in after-hours trading Tuesday</a>. The company reported preliminary first-quarter results that revealed disappointing sales and a significant inventory write-down.
The retailer said it expects first-quarter revenue of $1.1 billion, a 5% decline from the prior year.
According to Boss, American Eagle Outfitters is positioned to achieve long-term growth across both the AE and Aerie brands, with expected consolidated revenue growth of 3% to 5% and potential operating margin expansion driven by fixed cost leverage.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45404297/alcon-american-eagle-grail-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session" rel="noreferrer noopener">Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday&#8217;s Pre-Market Session</a>
However, the analyst cautions that recent softening in sales and unpredictable consumer behavior over the past six months could lead to uneven performance and pose execution risks.
Boss also highlights markdowns as a possible concern if demand volatility persists.
The analyst points out that for the first quarter, they are modeling a 1.0% year-over-year increase in SG&amp;A expenses, slightly above management's prior guidance for flat growth.
Boss attributes this minor difference to timing shifts in advertising investments, which appear to have caused a temporary uptick in spending compared to the company's flat expense plan.
The analyst revised the FY25 forecast downward, now expecting a 3.1% year-over-year revenue decline, compared to their earlier estimate of a 2.4% drop.
This reflects a low-single-digit percentage decline in revenue during the second half of FY25, as opposed to the analyst&#8217;s previous assumption of flat growth.
Additionally, Boss adjusted the FY25 gross margin estimate to 36.0%, down 320 basis points from the prior 38.1% forecast, while maintaining the same tariff impact assumption based on management's earlier $5–10 million guidance from March 12.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45413749/exclusive-apple-stock-could-benefit-from-smartphone-upgrade-cycle" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Apple Stock Could Benefit From Smartphone Upgrade Cycle, Poll Ranks Top Reason For Trade In (It&#8217;s Not The Camera)</a></li>
</ul>
Photo: Shutterstock

Equities

American Eagle Slumps After Weak Q1 Preview, Analyst Cuts Forecasts On Demand Concerns

A new 90-day pause and <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">lowered tariff amounts </a>between the United States and China have helped send the stock market higher with the S&amp;P 500 drifting back into positive territory for 2025.
The stock market gains have also helped the richest people in the world get richer. Here's a look at how the top 10 billionaires list is shaping up this year.
What Happened: The 10 richest people in the world <a href="https://www.benzinga.com/news/management/25/01/42771258/worlds-top-10-richest-people-gained-more-wealth-in-2024-than-costco-and-nikes-combined-valuation-how-elon-musk-warren-buffett-and-others-fared">added $518 billion</a> to their wealth in 2024, ending the year worth a combined $2.02 trillion.
After the stock market&#8217;s strong 2024, the wealth of the world's richest has been significantly different in 2025.
As of May 13, only four of the world&#8217;s ten richest individuals have posted gains in 2025. That&#8217;s up from just three in late March, and the group&#8217;s total combined wealth is inching closer to positive for the year after sharp declines in March and April.
Here are the current top 10 richest people in the world, with their 2025 gain or loss, as reported by <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>:
<ol class="wp-block-list">
<li>Elon Musk: $370 billion, -$62.6 billion</li>
<li>Jeff Bezos: $232 billion, -$6.9 billion</li>
<li>Mark Zuckerberg: $231 billion, +$24.2 billion</li>
<li>Larry Ellison: $187 billion, -$5.6 billion</li>
<li>Bill Gates: $170 billion, +$11.3 billion</li>
<li>Bernard Arnault: $165 billion, -$10.9 billion</li>
<li>Warren Buffett: $160 billion, +$17.9 billion</li>
<li>Steve Ballmer: $156 billion, +$9.2 billion</li>
<li>Larry Page: $146 billion, -$22.6 billion</li>
<li>Sergey Brin: $137 billion, -$21.0 billion</li>
</ol>
Together the top 10 richest people in the world are worth $1.95 trillion and have lost $67 billion in 2025. The names on the top 10 list are all the same with only their placements changing from the end of 2024.
The top four are the same, with Gates moving up two places, Arnault dropping one place, Buffett moving up three places, Ballmer moving down one place, Page moving down three places and Brin moving down two places.
<ul class="wp-block-list">
<li>You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/05/45335286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-64">check out five stocks flying under the radar that deserve your attention.</a></li>
</ul>
Why It's Important: Many of the world's richest have wealth tied to technology stocks, a sector hit hard by tariffs on China. With the 90-day pause and lower tariff amount, technology stocks have rebounded and helped boost the wealth of many people.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, is up 0.6% year-to-date in 2025 after spending months in the red.
While Musk&#8217;s wealth dropped significantly in 2025, it could be getting closer to returning to the <a href="https://www.benzinga.com/news/management/24/12/42444955/elon-musk-first-person-worth-400-billion-as-tesla-stock-hits-new-all-time-highs-how-2024-election-helped-could-lead-to-future-gains" target="_blank" rel="noopener">more than $400 billion</a> figure he had in December 2024, when Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock hit all-time highs.
Tesla stock is up 37% over the last month and shares are currently down 8.1% year-to-date in 2025, reversing trends from being down double digits on the year. Musk's wealth was $320 billion in late March and $310 billion in late April.
With five months complete in 2025, more than half the year remains to see if the 10 richest people in the world end with a positive wealth gain or if factors like tariffs and macroeconomic concerns send stocks lower again.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday">53 Facts And Figures About Tesla, SpaceX CEO Elon Musk </a></li>
</ul>
Photo: digihelion/shutterstock

Management

TSLA

Musk, Bezos Gain Billions After US-China Trade Deal, But The Wealthiest 10 Are Still Down $67B In 2025

Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) is enjoying a breakout moment &#8211; on the chart and in the headlines.
Shares of the crypto exchange have soared nearly 47% over the past month, outpacing Bitcoin's 22% gain and leaving the S&amp;P 500's 9% rally in the dust. 
The catalyst? A one-two punch: its upcoming May 19 inclusion into the<a href="https://www.benzinga.com//node/45416971"> S&amp;P 500 and its acquisition</a> of crypto options giant Deribit.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45415288/coinbase-ceo-brian-armstrong-invites-doge-staff-to-create-a-more-efficient-financial-system">Coinbase CEO Brian Armstrong Invites DOGE Staff To &#8216;Create A More Efficient Financial System&#8217;</a>
Coinbase&#8217;s technical setup is also lighting up.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14143012/Screenshot-2025-05-14-at-11.39.14-PM.png" alt="" class="wp-image-915505" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14143012/Screenshot-2025-05-14-at-11.39.14-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14143012/Screenshot-2025-05-14-at-11.39.14-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
COIN stock, at $259.55, is in a solid bullish trend as it trades above its 8-day simple moving average (SMA) of $215.29, 20-day SMA of $203.17, and 50-day SMA of $191.77. The stock has also broken above key resistance in its 200-day SMA, which sits at $225.25, recording a bullish breakout.
In terms of momentum, the Relative Strength Index (RSI) stands at 75.24, suggesting COIN stock may be in overbought territory — but strong buying pressure continues to fuel the rally. The Moving Average Convergence Divergence (MACD) indicator is at 11.81, underscoring bullish momentum.
Coinbase&#8217;s first quarter earnings, while mixed, delivered earnings per share of $1.94 versus the $1.85 estimate, a 4.86% surprise. Revenue came in lighter than expected at $2.03 billion versus $2.12 billion. But Wall Street didn't blink. The post-earnings move was driven largely by Coinbase becoming the first pure-play crypto firm to join the S&amp;P 500 Index &#8211; a major milestone that could significantly lift institutional ownership, which remains low relative to Coinbase's scale.
The announcement of its $2.9 billion acquisition of Deribit &#8211; a global leader with 75% market share in crypto options and $30 billion in open interest &#8211; only sweetened the deal for investors.
If technicals are any guide, COIN stock may not be done yet &#8211; though traders will want to keep a close eye on that rising RSI.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45403847/coinbase-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday">Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Technicals

Tech

COIN

Coinbase Explodes 47% Ahead Of S&P 500 Debut - Charts Flash Bullish Breakout

BMGL

Basel Medical Group Shares Halted On Circuit Breaker To The Downside, Stock Now Down -58.7%

WIIM

Dynatrace shares are trading higher following better-than-expected Q4 earnings and strong guidance.

AMGN

GILD

Shares of pharmaceutical stocks are trading lower. The sector may down on continued weakness amid President Trump's drug pricing executive order.

The U.S. Centers for Medicare &amp; Medicaid Services (CMS) on Monday issued a draft guidance for public comment on the third cycle of negotiations under the Medicare Drug Price Negotiation Program (Negotiation Program) to <a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">lower prescription drug prices</a>.
The draft guidance introduces new policies that would, for the first time, include drugs covered under Medicare Part B in the Medicare <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Drug Price Negotiation Program</a>.
The <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/cms-releases-draft-guidance-third-cycle-medicare-drug-price-negotiation-program-lower-drug-prices" rel="noreferrer noopener">guidance</a> also explains how CMS plans to renegotiate prices for some drugs already negotiated for 2026 or 2027.
It clarifies how drugmakers must make the negotiated prices available in those years and extends similar rules for Part D drugs through 2028.
The first round of negotiations, covering 10 Part D drugs, ended in August 2024. A second round, <a target="_blank" href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations" rel="noreferrer noopener">involving 15 more Part D drugs</a>, is currently underway.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
By Feb. 1, 2026, CMS will announce up to 15 additional drugs, covered under either Part D or Part B, for possible negotiation in the third round. Negotiations for this third group will happen in 2026, with new prices taking effect Jan. 1, 2028.
On the same date, CMS will publish the list of drugs selected for initial price negotiations for 2028 and announce any drugs picked for a first round of renegotiation. Those updated prices will also start on January 1, 2028.
CMS invites the public to comment on this draft guidance, including the drug selection process, how negotiated prices are implemented, and ways to improve the program.
The public comment period is open for 45 days. Comments must be submitted by June 26.
Goldman Sachs analyst Asad Haider says investors are concerned about fixed-combination drugs. The draft points out cases where one ingredient affects how the drug is absorbed but doesn&#8217;t treat the disease itself. This has led to worries that some subcutaneous (SC) versions of drugs that IV originally gave might be included in Medicare price negotiations under the Inflation Reduction Act (IRA) earlier than expected.
The prior CMS guidance issued under the Biden Administration suggested that sub-q formulations of IV drugs could be excluded from IRA price negotiations.
Stocks of companies with key SC drugs in focus, Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex Faspro, Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo Qvantig, and Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) subcutaneous pembrolizumab/Keytruda (in development), are trading lower.
&#8220;At a higher level, we view this development as another aspect of policy uncertainty that continues to persist, in addition to the Most Favored Nation Executive Order and potential for tariffs&#8230;In our view, this underscores a need for the industry to pursue novel innovations over incremental life cycle management strategies — a dynamic which we believe could lead to increased M&amp;A activity,&#8221; analyst Haider writes.
Price Action: JNJ stock is down 1.45% at $146.30, BMY stock is down 2.64% at $45.38, and MRK stock is down 2.46% at $74.74&nbsp;at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45409509/samsungs-1-7-billion-cooling-spree-buys-flaktgroup-to-target-data-center-boom" target="_blank" rel="noreferrer noopener">Samsung&#8217;s $1.7 Billion Cooling Spree &#8211; Buys FläktGroup To Target Data Center Boom</a></li>
</ul>
Image: Shutterstock

Comments

Hill & Smith

Hill & Smith (HSHPF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL